Nature Reviews Cancer Nature Reviews Cancer publishes a dynamic and accessible mix of Reviews, Perspectives, Progress and Highlight articles on the most important primary research papers. All Reviews and Perspectives are carefully commissioned, written by leaders in the field and subject to rigorous peer-review – so that readers receive independent, high-quality and authoritative articles in each issue. The journal’s broad scope captures the essence of modern multidisciplinary cancer research – integrating cancer biology with new approaches to treatment, diagnosis and prevention. Non-specialists will benefit from the glossary and highlighted references, busy scientists will appreciate the ‘At-a-glance’ summaries, and experts will value the insight provided by top names in their field. Nature Reviews Cancer is the premier teaching and reference resource in cancer and has become the ‘must read’ review journal of cancer researchers worldwide. http://feeds.nature.com/nrc/rss/current Nature Publishing Group en © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. Nature Reviews Cancer © 2025 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. [email protected]
  • Nature Reviews Cancer https://www.nature.com/uploads/product/nrc/rss.gif http://feeds.nature.com/nrc/rss/current <![CDATA[You’ve got exosomes]]> https://www.nature.com/articles/s41568-025-00887-8 <![CDATA[
    See More

    Nature Reviews Cancer, Published online: 24 October 2025; doi:10.1038/s41568-025-00887-8

    Metabolic dysfunction-associated steatotic liver disease (MASLD) is an independent risk factor for developing extra-hepatic cancers. Now, Li et al. uncover an exosome-driven metabolic connection between the steatotic liver and the breast that fosters cancer progression.]]> <![CDATA[You’ve got exosomes]]> Gabrielle Brewer doi:10.1038/s41568-025-00887-8 Nature Reviews Cancer, Published online: 2025-10-24; | doi:10.1038/s41568-025-00887-8 2025-10-24 Nature Reviews Cancer 10.1038/s41568-025-00887-8 https://www.nature.com/articles/s41568-025-00887-8 <![CDATA[Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer]]> https://www.nature.com/articles/s41568-025-00878-9 <![CDATA[

    Nature Reviews Cancer, Published online: 24 October 2025; doi:10.1038/s41568-025-00878-9

    FLASH radiotherapy demonstrates reduced complications in healthy tissues while effectively targeting tumours. In this Perspective, Vozenin et al. review the clinical implications, mechanistic basis and provide novel hypotheses for FLASH efficacy.]]>     <![CDATA[Mechanisms, challenges and opportunities for FLASH radiotherapy in cancer]]> Marie-Catherine VozeninPierre Montay-GruelPelagia TsoutsouCharles L. Limoli doi:10.1038/s41568-025-00878-9 Nature Reviews Cancer, Published online: 2025-10-24; | doi:10.1038/s41568-025-00878-9 2025-10-24 Nature Reviews Cancer 10.1038/s41568-025-00878-9 https://www.nature.com/articles/s41568-025-00878-9     <![CDATA[Unlocking the potential of FinnGen to advance cancer research]]> https://www.nature.com/articles/s41568-025-00885-w <![CDATA[

    Nature Reviews Cancer, Published online: 16 October 2025; doi:10.1038/s41568-025-00885-w

    Large biobank projects such as FinnGen have enabled systematic searches for inherited factors that causally influence a wide range of human traits, including cancer risk and outcome. These explorations provide genetic insights for various aspects of cancer research, including improved risk prediction, enhanced biomarker and drug target discovery, and personalized medicine.]]>     <![CDATA[Unlocking the potential of FinnGen to advance cancer research]]> Mervi AavikkoAoxing LiuMark Daly doi:10.1038/s41568-025-00885-w Nature Reviews Cancer, Published online: 2025-10-16; | doi:10.1038/s41568-025-00885-w 2025-10-16 Nature Reviews Cancer 10.1038/s41568-025-00885-w https://www.nature.com/articles/s41568-025-00885-w     <![CDATA[Exploiting metabolic cell death for cancer therapy]]> https://www.nature.com/articles/s41568-025-00879-8 <![CDATA[

    Nature Reviews Cancer, Published online: 15 October 2025; doi:10.1038/s41568-025-00879-8

    In this Review, Mao et al. discuss the regulation and interplay of the metabolic cell death pathways ferroptosis, disulfidptosis and cuproptosis and explore how these mechanisms can be harnessed for cancer therapies.]]>     <![CDATA[Exploiting metabolic cell death for cancer therapy]]> Chao MaoDadi JiangAlbert C. KoongBoyi Gan doi:10.1038/s41568-025-00879-8 Nature Reviews Cancer, Published online: 2025-10-15; | doi:10.1038/s41568-025-00879-8 2025-10-15 Nature Reviews Cancer 10.1038/s41568-025-00879-8 https://www.nature.com/articles/s41568-025-00879-8     <![CDATA[Decoding ferroptosis for cancer therapy]]> https://www.nature.com/articles/s41568-025-00864-1 <![CDATA[

    Nature Reviews Cancer, Published online: 10 October 2025; doi:10.1038/s41568-025-00864-1

    Although ferroptosis, an iron-dependent form of regulated cell death, is emerging as a therapeutic vulnerability in cancer, clinical translation is hindered by context-dependent regulation, a lack of predictive biomarkers and challenges in clinical trial design. In this Review, Wahida and Conrad examine the biological basis of ferroptosis, including its immunogenic potential, and outline the necessary steps towards translating ferroptosis-based therapies into the clinic.]]>     <![CDATA[Decoding ferroptosis for cancer therapy]]> Adam WahidaMarcus Conrad doi:10.1038/s41568-025-00864-1 Nature Reviews Cancer, Published online: 2025-10-10; | doi:10.1038/s41568-025-00864-1 2025-10-10 Nature Reviews Cancer 10.1038/s41568-025-00864-1 https://www.nature.com/articles/s41568-025-00864-1     <![CDATA[Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment]]> https://www.nature.com/articles/s41568-025-00869-w <![CDATA[

    Nature Reviews Cancer, Published online: 02 October 2025; doi:10.1038/s41568-025-00869-w

    Antibody–drug conjugates are rapidly expanding both in the clinical treatment of cancer and in preclinical development. In this Review, Zippelius et al. highlight the molecular interactions and immune system effects of these sophisticated drugs that drive their efficacy and toxicity.]]>     <![CDATA[Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment]]> Alfred ZippeliusSara M. TolaneyPaolo TarantinoJoseph P. BalthasarGreg M. Thurber doi:10.1038/s41568-025-00869-w Nature Reviews Cancer, Published online: 2025-10-02; | doi:10.1038/s41568-025-00869-w 2025-10-02 Nature Reviews Cancer 10.1038/s41568-025-00869-w https://www.nature.com/articles/s41568-025-00869-w     <![CDATA[Tamoxifen takes the wheel]]> https://www.nature.com/articles/s41568-025-00881-0 <![CDATA[

    Nature Reviews Cancer, Published online: 26 September 2025; doi:10.1038/s41568-025-00881-0

    In a recent study published in Nature Genetics, Kübler, Nardone et al. analysed the mechanisms underlying tamoxifen-associated uterine cancer and identified PI3K pathway activation as a key non-genetic driver.]]>     <![CDATA[Tamoxifen takes the wheel]]> Daniela Senft doi:10.1038/s41568-025-00881-0 Nature Reviews Cancer, Published online: 2025-09-26; | doi:10.1038/s41568-025-00881-0 2025-09-26 Nature Reviews Cancer 10.1038/s41568-025-00881-0 https://www.nature.com/articles/s41568-025-00881-0     <![CDATA[Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization]]> https://www.nature.com/articles/s41568-025-00882-z <![CDATA[

    Nature Reviews Cancer, Published online: 25 September 2025; doi:10.1038/s41568-025-00882-z

    Urine-based tumour DNA detection enables non-invasive profiling of urological malignancies and may inform on distant cancers via trans-renal cell-free DNA (cfDNA). Here the authors propose the ‘minimal urine methods in experiments’ (MUMIE) framework to enhance validation and standardization of urinary cfDNA biomarkers.]]>     <![CDATA[Unlocking the potential of urine-based liquid biopsy through improved reporting and standardization]]> Douglas G. WardRichard T. BryanAadel A. ChaudhuriJames HadfieldJennifer Perez-BozaRenske D. M. SteenbergenDiana M. VegaJennifer WhitingAlexander W. WyattLars Dyrskjøt doi:10.1038/s41568-025-00882-z Nature Reviews Cancer, Published online: 2025-09-25; | doi:10.1038/s41568-025-00882-z 2025-09-25 Nature Reviews Cancer 10.1038/s41568-025-00882-z https://www.nature.com/articles/s41568-025-00882-z